Skip to main content

and
  1. Article

    Open Access

    Natural history of nonhuman primates after conjunctival exposure to Ebola virus

    Transmission of Ebola virus (EBOV) primarily occurs via contact exposure of mucosal surfaces with infected body fluids. Historically, nonhuman primate (NHP) challenge studies have employed intramuscular (i.m.)...

    Robert W. Cross, Abhishek N. Prasad, Courtney B. Woolsey in Scientific Reports (2023)

  2. Article

    Open Access

    Combination therapy protects macaques against advanced Marburg virus disease

    Monoclonal antibodies (mAbs) and remdesivir, a small-molecule antiviral, are promising monotherapies for many viruses, including members of the genera Marburgvirus and Ebolavirus (family Filoviridae), and more re...

    Robert W. Cross, Zachary A. Bornholdt, Abhishek N. Prasad in Nature Communications (2021)

  3. Article

    Open Access

    Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages

    Lassa virus (LASV) is the causative agent of Lassa fever, an often-fatal hemorrhagic disease that is endemic in West Africa. Seven genetically distinct LASV lineages have been identified. As part of CEPI’s (Co...

    Megan L. Heinrich, Matthew L. Boisen, Diana K. S. Nelson in Scientific Reports (2020)

  4. Article

    Open Access

    Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

    A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and hu...

    Robert W. Cross, Zachary A. Bornholdt, Abhishek N. Prasad in Nature Communications (2020)

  5. Article

    Open Access

    Immune correlates of postexposure vaccine protection against Marburg virus

    Postexposure immunization can prevent disease and reduce transmission following pathogen exposure. The rapid immunostimulatory properties of recombinant vesicular stomatitis virus (rVSV)-based vaccines make th...

    Courtney Woolsey, Allen Jankeel, Demetrius Matassov, Joan B. Geisbert in Scientific Reports (2020)

  6. Article

    Open Access

    Rational design of universal immunotherapy for TfR1-tropic arenaviruses

    Certain arenaviruses that circulate in rodent populations can cause life-threatening hemorrhagic fevers when they infect humans. Due to their efficient transmission, arenaviruses pose a severe risk for outbrea...

    Hadas Cohen-Dvashi, Ron Amon, Krystle N. Agans, Robert W. Cross in Nature Communications (2020)

  7. Article

    Open Access

    Antagonism of STAT1 by Nipah virus P gene products modulates disease course but not lethal outcome in the ferret model

    Nipah virus (NiV) is a pathogenic paramyxovirus and zoononis with very high human fatality rates. Previous protein over-expression studies have shown that various mutations to the common N-terminal STAT1-bindi...

    Benjamin A. Satterfield, Viktoriya Borisevich, Stephanie L. Foster in Scientific Reports (2019)

  8. Article

    Open Access

    Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever

    Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne bunyavirus, can cause a life-threatening hemorrhagic syndrome in humans but not in its animal host. The virus is widely distributed throughout southe...

    Sergio E. Rodriguez, Robert W. Cross, Karla A. Fenton in Scientific Reports (2019)

  9. Article

    Open Access

    Author Correction: Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants

    A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.

    Krista Versteeg, Andrea R. Menicucci, Courtney Woolsey, Chad E. Mire in Scientific Reports (2019)

  10. Article

    Open Access

    Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever

    Lassa fever, a hemorrhagic fever caused by Lassa virus (LASV), is endemic in West Africa. It is difficult to distinguish febrile illnesses that are common in West Africa from Lassa fever based solely on a pati...

    Matthew L. Boisen, Jessica N. Hartnett, Jeffrey G. Shaffer in Scientific Reports (2018)

  11. Article

    Open Access

    Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants

    Zaire Ebolavirus (ZEBOV) continues to pose a significant threat to human health as highlighted by the recent epidemic that originated in West Africa and the ongoing outbreak in the Democratic Rep...

    Krista Versteeg, Andrea R. Menicucci, Courtney Woolsey, Chad E. Mire in Scientific Reports (2017)

  12. Article

    Open Access

    Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy

    Nipah virus (NiV) is a paramyxovirus that causes severe disease in humans and animals. There are two distinct strains of NiV, Malaysia (NiVM) and Bangladesh (NiVB). Differences in transmission patterns and mortal...

    Chad E. Mire, Benjamin A. Satterfield, Joan B. Geisbert in Scientific Reports (2016)

  13. Article

    Open Access

    Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

    Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been i...

    James E. Robinson, Kathryn M. Hastie, Robert W. Cross in Nature Communications (2016)

  14. Article

    Open Access

    The immunomodulating V and W proteins of Nipah virus determine disease course

    The viral determinants that contribute to Nipah virus (NiV)-mediated disease are poorly understood compared with other paramyxoviruses. Here we use recombinant NiVs (rNiVs) to examine the contributions of the ...

    Benjamin A. Satterfield, Robert W. Cross, Karla A. Fenton in Nature Communications (2015)